Lasofoxifene Tartrate

Phase 2

Lasofoxifene Tartrate is one of 2 therapeutic programs targeting Vulvo Vaginal Atrophy (VVA). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Vulvo Vaginal Atrophy (VVA)Recruiting

Vulvo Vaginal Atrophy (VVA)Phase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Vulvo Vaginal Atrophy (VVA)

#DrugCompanyPhaseTrials

Lasofoxifene Tartrate (AZU-101)

AAzure Biotech Inc.

Phase 2

1 2

Lasofoxifene Tartrate

AAzure Biotech Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Vulvo Vaginal Atrophy (VVA)

NCT06197568

Clinical

Trials by Indication[1]

Vulvo Vaginal Atrophy (VVA)1 trial

A Double-blind, Randomized, Placebo-controlled Proof oF Concept Clinical Study to Evaluate the Safety, Pharmacokinetics, AND Pharmacodynamics of Vaginal AZU-101 (Lasofoxifene Tartrate) in Postmenopausal Women

Recruiting·AAzure Biotech Inc.·Phase 2·NCT06197568·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lasofoxifene Tartrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lasofoxifene Tartrate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Azure Biotech Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAzure Biotech Inc.

Lasofoxifene Tartrate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Vulvo Vaginal Atrophy (VVA)1 trial

References

Drug Info

Quick Facts

Related News